Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Brain Tumor
Conditions
Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm
Trial Timeline
Aug 8, 2019 → Jan 13, 2025
NCT ID
NCT04023669About Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim is a phase 1 stage product being developed by Eli Lilly for Brain Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT04023669. Target conditions include Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04023669 | Phase 1 | Completed |
Competing Products
20 competing products in Brain Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Endocrine therapy | Eli Lilly | Phase 1/2 | 41 |
| Duloxetine + Sugar pill | Eli Lilly | Phase 2 | 52 |
| Neurosteroid enantiomer | Oragenics | Phase 2 | 44 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| filgrastim + exatecan mesylate | Daiichi Sankyo | Phase 1 | 33 |
| Eribulin Mesylate | Eisai | Phase 1 | 33 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 52 |
| Palonosetron (Aloxi) and Dexamethasone | Eisai | Phase 2 | 52 |
| GLIADEL | Eisai | Phase 2 | 52 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 77 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 77 |
| abemaciclib + abemaciclib | Eli Lilly | Phase 2 | 52 |
| JNJ-17299425 | Johnson & Johnson | Phase 2 | 52 |
| ABT-888 | AbbVie | Phase 1 | 33 |
| Veliparib + Placebo | AbbVie | Phase 2 | 52 |
| Iressa (Gefitinib) | AstraZeneca | Phase 2 | 52 |
| Trastuzumab deruxtecan | AstraZeneca | Phase 2 | 52 |
| Exenatide | AstraZeneca | Approved | 85 |
| AZD5213 | AstraZeneca | Phase 1 | 33 |
| Vorinostat | Merck | Phase 1 | 33 |